Website
News25/Ratings0
News · 26 weeks31-44%
2025-10-262026-04-19
Mix1990d
- Other13(68%)
- Insider3(16%)
- Offering2(11%)
- SEC Filings1(5%)
Latest news
25 items- INSIDERSEC Form 4 filed by Feldschuh Michael Richard4 - DAXOR CORP (0000027367) (Issuer)
- PRDaxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology CenterOak Ridge, TN, April 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, continues its strategic expansion with the launch of a new BVA program at a premier cardiology facility in Southwest Ohio. This integration brings Daxor's state-of-the-art testing to a high-volume heart failure care setting, targeting the growing market for chronic disease management. By leveraging Daxor's proprietary, Tennessee-based ezBVA Lab workflow, the facility gains access to 24-hour turnaround on gold-standard blood volume metrics without the need for onsite laboratory infrastructure. This "lab-as-a-service" model allows for rapid, data-driven
- SECAmendment: SEC Form N-CEN/A filed by Daxor CorporationN-CEN/A - DAXOR CORP (0000027367) (Filer)
- INSIDERSEC Form 4 filed by Michel Robert J4 - DAXOR CORP (0000027367) (Issuer)
- SECSEC Form 40-17F2 filed by Daxor Corporation40-17F2 - DAXOR CORP (0000027367) (Subject)
- PRDaxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026OAK RIDGE, TN, March 26, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces that new clinical data evaluating the accuracy of capillary leak detection scores compared to BVA was presented at the Society for Critical Care Medicine (SCCM) 2026 Critical Care Congress. The study, titled, "Mechanistic Specificity of Capillary Leak Indices: Validation in Heart Failure as a Negative Control," was featured during the Research Snapshot Theater. The research investigated the relationship between traditional clinical scoring methods and direct, in-vivo measurement of albumin escape using Daxor's Blood Volume Analyzer (BV
- INSIDERSEC Form 4 filed by Jefferies John4 - DAXOR CORP (0000027367) (Issuer)
- PRDaxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced ReadmissionsOak Ridge, TN, March 17, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces its participation as an exhibitor at the American College of Cardiology (ACC.26) Annual Scientific Session in New Orleans, LA, March 28–30, 2026. Daxor will showcase its new, rapid, portable Blood Volume Analyzer (BVA). As the only FDA-cleared diagnostic providing greater than 95% accurate, direct quantification of a patient's total blood, plasma, and red cell volume, the BVA replaces subjective guesswork with definitive data. This precision is a critical benefit of BVA, particularly for health systems navigating the $3.5 billion annua
- SECSEC Form N-CEN filed by Daxor CorporationN-CEN - DAXOR CORP (0000027367) (Filer)
- PRDaxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care CongressAdvancing Precision Fluid Management in the ICU to Reduce Mortality and Hospital Length of Stay Oak Ridge, TN, March 10, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it will showcase its new, portable blood volume analyzer at the Society for Critical Care Medicine (SCCM) 2026 Critical Care Congress (Booth #906) at McCormick Place in Chicago, IL, from March 22–24. The new device delivers rapid, lab-quality results making Blood Volume Analysis (BVA) easier to implement across diverse clinical settings. This streamlined workflow positions Daxor to address the high costs associated with the more than five m
- PRDaxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026Oak Ridge, TN, March 09, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces that CEO and President Michael Feldschuh will participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026 being held virtually on March 10 -11, 2026. Mr. Feldschuh will deliver a 30-minute presentation on March 10 at 2:00 PM ET, and conduct virtual one-on-one meetings with institutional investors on March 11. Event:iAccess Alpha Virtual Best Ideas Summer ConferenceDate:March 10, 2026Time:2:00 PM ET (presentation)Webcast:https://www.webcaster5.com/Webcast/Page/3157/53749 For more information about the iAccess Virtu
- PRDaxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to ShareholdersOak Ridge, TN, March 03, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 2, 2026 from CEO & President, Michael Feldschuh. Dear Valued Shareholders, "To measure is to know. If you cannot measure it, you cannot improve it." — Lord Kelvin Lord Kelvin's timeless scientific principle perfectly encapsulates the mission of Daxor Corporation. In medicine, you cannot effectively treat what you cannot accurately measure. Looking back at the entirety of 2025, our commitment to replacing clinical guesswork with
- PRDaxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per ShareStrategic Realignment to Clinical Growth Supported by FDA 510(k) Clearance for Next-Generation Blood Volume Analyzer Oak Ridge, TN, March 03, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces financial and operating results for the fiscal year ended December 31, 2025. The company reported a transformative year characterized by significant growth in its operating division and a substantial increase in total net assets. FDA Milestone & Commercial Momentum The most significant corporate highlight of the year was the receipt of FDA 510(k) clearance in August 2025 for Daxor's next-generation rapid, compact, and
- SECSEC Form N-CSR filed by Daxor CorporationN-CSR - DAXOR CORP (0000027367) (Filer)
- PRDaxor Scales Outpatient Presence; Launches BVA Diagnostic Program in TennesseeExpansion Leverages Daxor's ezBVA Lab to Deliver 98% Accurate Diagnostics with Zero Capital Investment Oak Ridge, TN, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, continues its strategic expansion into the outpatient cardiology market with the opening of a new BVA program at a leading healthcare facility in Southern Middle Tennessee. This integration brings Daxor's state-of-the-art testing to a high-volume preventative care setting, driving clinical excellence in chronic disease management. Utilizing Daxor's proprietary, Tennessee-based ezBVA Lab workflow, the facility will benefit from a 24-hour turnaround t
- PRDaxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic BusinessOak Ridge, TN, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announced its intention to transition its primary regulatory reporting framework from the Investment Company Act of 1940 (the Investment Company Act) to the Securities Exchange Act of 1934 (the "Exchange Act"), subject to its completion of required regulatory filings and approvals. This transition reflects the sustained rapid scaling and strategic maturation of the Company's core diagnostic technology operating business. The Company's principal focus remains the development and commercialization of its market-leading Blood Volume Analysis (BVA) t
- SECSEC Form 40-8F-2 filed by Daxor Corporation40-8F-2 - DAXOR CORP (0000027367) (Filer)
- SECDaxor Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - DAXOR CORP (0000027367) (Filer)
- SECSEC Form 424B4 filed by Daxor Corporation424B4 - DAXOR CORP (0000027367) (Filer)
- PRDaxor Corporation Announces $9 Million Registered Direct OfferingOAK RIDGE, TN, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NasdaqCM: DXR) ("Daxor" or the "Company") announced today that it has entered into a definitive agreement with fundamental investors for the purchase and sale of an aggregate of 765,958 shares of its common stock (the "Shares") at a purchase price per Share of $11.75. The offering is expected to close on or about January 26, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering to the Company are expected to be approximately $9 million, before deducting placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds fr
- SECSEC Form 424B3 filed by Daxor Corporation424B3 - DAXOR CORP (0000027367) (Filer)
- SECDaxor Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - DAXOR CORP (0000027367) (Filer)
- SECSEC Form 424B3 filed by Daxor Corporation424B3 - DAXOR CORP (0000027367) (Filer)
- SECSEC Form EFFECT filed by Daxor CorporationEFFECT - DAXOR CORP (0000027367) (Filer)
- SECAmendment: SEC Form N-2/A filed by Daxor CorporationN-2/A - DAXOR CORP (0000027367) (Filer)